

Anti-Complement component C3a/C3a(desArg)/C3 (human)

Mouse monoclonal antibody, biotinylated

Subclass: IgG1/k

PRODUCT NO.

GAU 017-01 B

Clone: D17/1

SPECIFICITY	Recognizes an epitope that is present on human C3, C3a and C3a (desArg). Does not cross-react with C4a or C5a.
IMMUNOGEN	Human C3a
TESTED APPLICATIONS	ELISA, IHC
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	GAU 017-01 recognizes different epitopes on the 9 kDa C3a than GAU 013-16. No reaction is seen with a synthetic octapeptide representing the C3a C-terminal.

PRESENTATION

Content:	150 µL, 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Biotinylated
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION **ELISA:** GAU 017-01 can be used as a biotinylated detection antibody in sandwich ELISA with GAU 013-16 capture antibody (1-5). Does not inhibit the biological activity of C3a (1).

IHC: GAU 017-01B was used in IHC on human appendix section.

TARGET Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).

- REFERENCES**
1. Nezlin R, Freywald A, Oppermann M (1993) Proteins separated from human IgG molecules. Mol. Immunol. 30:935-940.
 2. Oppermann M, Liebmann F, Götze O. (1987) Purification and quantification of human C3a anaphylatoxin using monoclonal antibodies. Complement 4:205-206
 3. Oppermann M, Haubitz M, Quintin E, Götze O (1988) Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and Factor B. Klin Wochenschr 66:857-864
 4. Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DBR, Köhl J, Finkelman FD (2009) Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol 123:342-351.
 5. Thomas SN, van der Vlies AJ, O'Neil CP, Reddy ST, Yu SS, Giorgio TD, Swartz MA, Hubbell JA (2011) Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 32: 2194-2203.

This product is not for further manufacture

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.